AR120244A1 - INHIBICIÓN DE INTEGRINA a4b7 HUMANA - Google Patents

INHIBICIÓN DE INTEGRINA a4b7 HUMANA

Info

Publication number
AR120244A1
AR120244A1 ARP200102870A ARP200102870A AR120244A1 AR 120244 A1 AR120244 A1 AR 120244A1 AR P200102870 A ARP200102870 A AR P200102870A AR P200102870 A ARP200102870 A AR P200102870A AR 120244 A1 AR120244 A1 AR 120244A1
Authority
AR
Argentina
Prior art keywords
ethyl
biphenyl
methylpentanamido
fluoro
propanoic
Prior art date
Application number
ARP200102870A
Other languages
English (en)
Inventor
Matthew G Bursavich
Dan Cui
James E Dowling
Kristopher N Hahn
Bryce A Harrison
Fu Lin
- Lippa Blaise S Yang
Bruce N Rogers
Dawn M Troast
Cheng Zhong
Kyle D Konze
Aleksey I Gerasyuto
Byungchan Kim
Salma Rafi
Tyler Day
Eugene Hickey
Evelyne Houang
Robert Zahler
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of AR120244A1 publication Critical patent/AR120244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Moléculas pequeñas antagonistas de la integrina humana a4b7, y métodos para usarlas en el tratamiento de varias enfermedades y afecciones. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), donde Rᵃ, Rᵇ, y Rᶜ se seleccionan en forma independiente entre el grupo que consiste en H, Me, haluro, CF₃, C(H)F₂, C(F)H₂, y -C₁₋₅alquilen-N-(Rˣ)(Rʸ); con la condición de que al menos uno de Rᵃ, Rᵇ, y Rᶜ es -C₁₋₅alquilen-N-(Rˣ)(Rʸ); Rˣ y Rʸ se seleccionan en forma independiente entre el grupo que consiste en H y C₁₋₆-alquilo sustituido o no sustituido; o Rˣ y Rʸ tomados junto con el N al que están unidos forman un anillo de 4 - 6 miembros; R¹ es metilo, etilo, n-propilo, iso-propilo, n-butilo, iso-butilo, sec-butilo, o t-butilo; R² es el compuesto de fórmula (2); R³ᵃ y R³ᵇ se seleccionan en forma independiente entre el grupo que consiste en H, C₁₋₅-alquilo, C₃₋₆-cicloalquilo, heterocicloalquilo de 3 - 6 miembros sustituido o no sustituido, -OH, -CN, haluro, CF₃, C(H)F₂, C(F)H₂, -C₁₋₄-alcoxi, -OCF₃, y C₁₋₄-alquilen-C₁₋₄-alcoxi sustituido o no sustituido; con la condición de que R³ᵃ y R³ᵇ no son ambos H; R³ᶜ, y R³ᵈ son H; R⁴ es H; R⁵ᵃ, y R⁵ᵉ son en forma independiente metilo; R⁵ᵇ, y R⁵ᶜ se seleccionan en forma independiente entre el grupo que consiste en H, CN, haluro, CF₃, C(H)F₂, C(F)H₂, C₁₋₅-alquilo sustituido o no sustituido, C₃₋₆-cicloalquilo sustituido o no sustituido, heterocicloalquilo de 3 - 6 miembros sustituido o no sustituido, hidroxilo, y C₁₋₄-alcoxi; R⁵ᵈ es H; y donde el compuesto de fórmula (1) se selecciona entre el grupo que consiste en: a. ácido (S)-3-(4,5-difluoro-2’,6’-dimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-il)etil)-4-metil-2-oxopiridin-1(2H)-il)-4-metilpentanamido)propanoico; b. ácido (S)-3-((S)-2-(5-(2-(azetidin-1-il)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)-3-(4-fluoro-2’,6’-dimetil-5-(trifluorometil)-[1,1’-bifenil]-3-il)propanoico; c. ácido (S)-3-((S)-2-(5-(2-(azetidin-1-il)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)-3-(3’,4-difluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)propanoico; d. ácido (S)-3-((S)-2-(5-(2-(azetidin-1-il)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)-3-(4-fluoro-3’-metoxi-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)propanoico; e. ácido (S)-3-(4,4’-difluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(5-(2-(dimetilamino)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)propanoico; f. ácido (S)-3-(5-cloro-4-fluoro-2’,6’-dimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(5-(2-(3-metoxiazetidin-1-il)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)propanoico; g. ácido (S)-3-((S)-2-(5-(2-(dimetilamino)etil)-2-oxo-4-(trifluorometil)piridin-1(2H)-il)-4-metilpentanamido)-3-(4-fluoro-2’,4’,5,6’-tetrametil-[1,1’-bifenil]-3-il)propanoico; h. ácido (S)-3-(4,4’-difluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(3-(difluorometil)-5-(2-(dimetilamino)etil)-2-oxopiridin-1(2H)-il)-4-metilpentanamido)propanoico; i. ácido (S)-3-((S)-2-(5-(2-(dimetilamino)etil)-4-metil-2-oxopiridin-1(2H)-il)-5-metilhexanamido)-3-(4-fluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)propanoico; j. ácido (S)-3-(4-fluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-il)etil)-2-oxopiridin-1(2H)-il)-4-metilpentanamido)propanoico; y k. ácido (S)-3-(4-fluoro-2’,5,6’-trimetil-[1,1’-bifenil]-3-il)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropirrolidin-1-il)etil)-2-oxopiridin-1(2H)-il)-4-metilpentanamido)propanoico; o una sal farmacéuticamente aceptable del mismo.
ARP200102870A 2019-10-16 2020-10-16 INHIBICIÓN DE INTEGRINA a4b7 HUMANA AR120244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
AR120244A1 true AR120244A1 (es) 2022-02-09

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102870A AR120244A1 (es) 2019-10-16 2020-10-16 INHIBICIÓN DE INTEGRINA a4b7 HUMANA

Country Status (22)

Country Link
US (3) US11104661B1 (es)
EP (2) EP4045039A4 (es)
JP (6) JP7437495B2 (es)
KR (2) KR20220102669A (es)
CN (2) CN115087444A (es)
AR (1) AR120244A1 (es)
AU (2) AU2020366435A1 (es)
BR (1) BR112022007284A2 (es)
CA (1) CA3154269A1 (es)
CL (1) CL2022000959A1 (es)
CO (1) CO2022005759A2 (es)
CR (1) CR20220205A (es)
CU (1) CU20220027A7 (es)
DO (1) DOP2022000081A (es)
EC (1) ECSP22038978A (es)
IL (1) IL292296A (es)
MX (1) MX2022004406A (es)
PE (1) PE20221829A1 (es)
TW (5) TWI802477B (es)
UY (1) UY38926A (es)
WO (3) WO2021076890A1 (es)
ZA (2) ZA202203872B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114489A1 (es) 2018-04-12 2020-09-09 Morphic Therapeutic Inc ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
MX2022004406A (es) * 2019-10-16 2022-08-25 Morphic Therapeutic Inc INHIBICIÓN DE INTEGRINA A4ß7 HUMANA.
JP2022551972A (ja) 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の治療のためのヘテロアリール－ビフェニルアミン
WO2023125182A1 (zh) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 一种丙酸衍生物及其在医药上的应用
WO2024051819A1 (zh) * 2022-09-09 2024-03-14 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
WO2024138042A1 (en) 2022-12-22 2024-06-27 Xinthera, Inc. Alpha4 beta7 integrin antagonists and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3034046B2 (ja) 1993-03-31 2000-04-17 ジー．ディー．サール アンド カンパニー 血小板凝集阻害剤としての１−アミジノフェニル−ピロリドンピペリジノンアゼチノン
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
WO2000068188A1 (en) * 1999-05-07 2000-11-16 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
WO2001021584A1 (en) 1999-09-24 2001-03-29 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
WO2002018340A1 (en) * 2000-08-30 2002-03-07 Pharmacia Corporation GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
KR101364276B1 (ko) 2004-09-03 2014-02-20 제넨테크, 인크. 인간화 항-베타７ 길항제 및 그의 용도
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
DE602006019731D1 (de) 2005-06-09 2011-03-03 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
WO2012135589A1 (en) 2011-03-31 2012-10-04 Genentech, Inc. Methods of administering beta7 integrin antagonists
EP2903691B1 (en) 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
RU2016136716A (ru) 2014-03-27 2018-04-28 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
CN107257693A (zh) 2015-02-26 2017-10-17 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
TW201835078A (zh) * 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
AR114489A1 (es) * 2018-04-12 2020-09-09 Morphic Therapeutic Inc ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA
JP7192139B2 (ja) 2018-10-30 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリン阻害剤としてのキノリン誘導体
CA3115820A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
MX2022004406A (es) 2019-10-16 2022-08-25 Morphic Therapeutic Inc INHIBICIÓN DE INTEGRINA A4ß7 HUMANA.

Also Published As

Publication number Publication date
JP2022548809A (ja) 2022-11-22
CO2022005759A2 (es) 2022-05-20
PE20221829A1 (es) 2022-11-29
JP7209116B2 (ja) 2023-01-19
CU20220027A7 (es) 2022-12-12
WO2021076902A1 (en) 2021-04-22
CN115087444A (zh) 2022-09-20
CR20220205A (es) 2022-07-22
JP2023036958A (ja) 2023-03-14
US11370773B1 (en) 2022-06-28
UY38926A (es) 2021-05-31
TW202222793A (zh) 2022-06-16
TW202126624A (zh) 2021-07-16
TW202244040A (zh) 2022-11-16
EP4228634A1 (en) 2023-08-23
TWI775182B (zh) 2022-08-21
CA3154269A1 (en) 2021-04-22
JP2022542184A (ja) 2022-09-29
BR112022007284A2 (pt) 2022-07-05
DOP2022000081A (es) 2022-07-31
ZA202303992B (en) 2024-06-26
US20240174632A1 (en) 2024-05-30
JP7437495B2 (ja) 2024-02-22
CN116783161A (zh) 2023-09-19
EP4045039A1 (en) 2022-08-24
AU2021361031A1 (en) 2023-06-08
TWI802477B (zh) 2023-05-11
TWI791304B (zh) 2023-02-01
AU2020366435A1 (en) 2022-04-21
MX2022004406A (es) 2022-08-25
CL2022000959A1 (es) 2023-04-28
TWI840047B (zh) 2024-04-21
US11104661B1 (en) 2021-08-31
JP7437490B2 (ja) 2024-02-22
JP2023500437A (ja) 2023-01-06
WO2022081983A1 (en) 2022-04-21
KR20230088376A (ko) 2023-06-19
WO2021076890A1 (en) 2021-04-22
ZA202203872B (en) 2024-01-31
JP2024054293A (ja) 2024-04-16
IL292296A (en) 2022-06-01
ECSP22038978A (es) 2022-06-30
KR20220102669A (ko) 2022-07-20
JP7500785B2 (ja) 2024-06-17
WO2021076890A4 (en) 2021-06-10
TW202332675A (zh) 2023-08-16
TW202315868A (zh) 2023-04-16
JP2024054296A (ja) 2024-04-16
EP4045039A4 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
AR120244A1 (es) INHIBICIÓN DE INTEGRINA a4b7 HUMANA
JP2016534134A5 (es)
RU2019106484A (ru) Гетероциклическое соединение
JP4592819B2 (ja) 抗寄生虫剤
TW201920081A (zh) 作為鈉通道調節劑的羧醯胺
NZ627750A (en) Carbamate compounds and of making and using same
JP2016526540A5 (es)
RU2015121424A (ru) Комбинированная терапия
RU2013153529A (ru) Новые соединения и композиции для ингибирования nampt
JP2016500661A5 (es)
RU2017146408A (ru) Тетразамещенные алкеновые соединения и их применение
JP2016513660A5 (es)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JPH08510736A (ja) 炎症治療用置換オキサゾリル化合物
EA201591775A1 (ru) Замещенные ароматические соединения и связанный с ними способ лечения фиброза
JP2016525136A5 (es)
JP2019501130A5 (es)
JP2016539180A5 (es)
AR010743A1 (es) Compuestos de pirazol, utiles como inhibidores de la liberacion de acidos grasos mediada por la fosfolipasa a2 secretora no pancreatica humana.procedimientos para preparar dichos compuestos y composiciones farmaceuticas formuladas con dichos compuestos
JP2013522310A (ja) Ｈｅｃ１活性の調節因子およびそのための方法
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2018048143A5 (es)
JP2015504076A5 (es)
JP2017508794A5 (es)
JP2016528273A5 (es)